China's Kexing Vaccine "entry into the WTO" is essential to contain the global epidemic

China News Service, June 5th.

According to reports, on June 1st, the new inactivated vaccine "Kierlai Fu" developed by China Beijing Kexing Zhongwei Biotechnology Co.

"Nature" magazine quoted Murat Akova, a clinical researcher of infectious diseases at the University of Hatchetpe in Turkey, as saying that Koxing vaccine, as a safe and effective new crown vaccine, "will make a significant contribution to the global fight against the new crown epidemic.

The report pointed out that Kexing vaccine is also the second Chinese new crown vaccine to be included in the WHO's emergency use list after the Sinopharm vaccine.

According to reports, worldwide, the cumulative supply of Kexing vaccine exceeds 600 million doses, and it is continuing to carry out vaccination activities in more than 40 countries and regions including Chile and Botswana.

A spokesperson for the Global Alliance for Vaccines and Immunization (GAVI) said, “GAVI welcomes the news that Kexing Vaccine has been included in the WHO’s emergency use list, because it means that the world has another safe and effective tool to combat this epidemic.

The article mentioned that a trial conducted in the Brazilian town of Serana showed that Coxing vaccine can play a major role in the fight against the epidemic.

Ricardo Palacios, a researcher in charge of the trial at the Butantin Institute, mentioned that although nearly 40% of the population commutes to the epidemic-ravaged areas every day, the Coxing vaccine can protect entire towns.